GLP-1 vs Phentermine: Old School vs New School Weight Loss

Introduction

Phentermine has been on the US market since 1959. For more than 60 years it was the most prescribed weight loss medication in America, and in many practices it still is. It’s cheap, available everywhere, and produces real short-term weight loss.

GLP-1 receptor agonists, by contrast, are the new wave. Semaglutide hit the obesity market in 2021. Tirzepatide followed in 2023. They produce two to three times the weight loss of phentermine, with a very different side effect profile and a very different price tag.

If you’re comparing the two, the right question isn’t which is “better” in the abstract. It’s which fits your body, your timeline, your budget, and the kind of side effects you can live with. Phentermine and GLP-1s work through completely different mechanisms, and that drives almost every difference between them.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Does Each Medication Actually Work?

Phentermine is a sympathomimetic amine. Structurally it’s related to amphetamine, though it has a much weaker abuse profile. It triggers release of norepinephrine in the central nervous system, which suppresses appetite and increases resting energy expenditure. The mechanism is essentially “turn up the sympathetic nervous system.”

Quick Answer: Phentermine averages 5% to 8% weight loss over 12 weeks; semaglutide hits 14.9% at 68 weeks (STEP 1, Wilding et al. 2021 NEJM)

GLP-1 receptor agonists like semaglutide and tirzepatide mimic an endogenous gut hormone. They slow gastric emptying, increase satiety signaling in the hypothalamus and brainstem, improve glucose-dependent insulin secretion, and reduce food reward responses in the brain’s reward circuits. The mechanism is “amplify the body’s own satiety signaling.”

The practical result: phentermine makes you less hungry by ramping up adrenergic tone. GLP-1s make you less hungry by making food feel less interesting and making you feel full faster. The first feels stimulant-like. The second feels almost like the absence of hunger.

Which Produces More Weight Loss?

GLP-1s win by a wide margin, especially over longer time horizons. A 2014 meta-analysis of phentermine monotherapy (Hendricks et al. Obesity) found average weight loss of 6.7% over 12 weeks and around 7% to 9% at 6 months in the best-performing trials. Real-world results are typically lower, in the 5% range.

The STEP 1 trial (Wilding et al. 2021 NEJM) tested semaglutide 2.4 mg weekly in 1,961 adults with obesity. Mean weight loss was 14.9% at 68 weeks versus 2.4% on placebo. Around 50% of patients lost at least 15% of body weight; a third lost at least 20%.

SURMOUNT-1 (Jastreboff et al. 2022 NEJM) tested tirzepatide in 2,539 adults with obesity. At the 15 mg dose, mean weight loss was 20.9% at 72 weeks. More than half lost at least 20%. About a third lost at least 25%.

So phentermine produces roughly a third the weight loss of semaglutide and a quarter the weight loss of tirzepatide.

How Long Can You Take Each Medication?

This is one of the biggest practical differences. The FDA approved phentermine in 1959 for short-term use, typically 12 weeks. The label hasn’t changed. Some clinicians prescribe it longer off-label, but the official position is short-term only because the original trials didn’t study chronic use and because of theoretical concerns about cardiovascular effects.

GLP-1 receptor agonists are approved for chronic weight management. Semaglutide and tirzepatide are designed to be taken indefinitely, the way someone with hypertension takes a blood pressure medication. The STEP 4 trial (Rubino et al. 2021 JAMA) and SURMOUNT-4 (Aronne et al. 2024 JAMA) confirmed what happens when you stop: weight returns. STEP 4 patients who switched to placebo at week 20 regained 6.9% by week 68, while those who continued semaglutide lost another 7.9%.

This shapes the entire decision. Phentermine is a sprint. GLP-1s are a marathon, possibly a permanent one.

What’s the Side Effect Profile?

Phentermine’s most common side effects are stimulant-driven: increased heart rate, elevated blood pressure, insomnia, dry mouth, jitteriness, anxiety, and constipation. These hit hardest in the first weeks and often improve. Phentermine is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, history of stimulant abuse, or pregnancy.

GLP-1 side effects are mostly gastrointestinal: nausea, vomiting, diarrhea, constipation. They occur in 20% to 40% of patients during the dose-escalation phase and usually settle. Less common: pancreatitis (rare), gallbladder disease (modest increased risk), heart rate increase of 2 to 5 bpm. GLP-1s tend to lower blood pressure by 4 to 6 mmHg systolic on average, the opposite of phentermine.

For patients with high blood pressure, atherosclerotic cardiovascular disease, or a history of stimulant intolerance, GLP-1s have a more favorable profile. For patients with bad GI tolerance, phentermine may be easier.

What Does Each Cost?

Phentermine generic is dirt cheap. A 30-day supply of 37.5 mg tablets often costs $10 to $40 cash, often less than $10 with GoodRx. Insurance coverage is variable but copays are usually low.

GLP-1s are expensive. Brand Wegovy® lists at around $1,349/month, brand Zepbound® at around $1,086/month. Compounded semaglutide and tirzepatide through telehealth platforms like TrimRx typically run $200 to $500/month. Even at compounded prices, that’s 5 to 10 times the cost of phentermine.

Over 12 weeks, phentermine might cost $30 to $120 total. Over 12 months, compounded GLP-1 might cost $2,400 to $6,000. The cost gap is real and it matters for many patients.

Key Takeaway: Phentermine is FDA-approved for short-term use only (typically 12 weeks); GLP-1s are approved for chronic weight management

Can You Combine Them?

Yes, and combination therapy is a recognized approach in obesity medicine. Phentermine plus topiramate (Qsymia) is FDA-approved as a combination tablet. Some obesity medicine physicians use phentermine alongside a GLP-1 in patients who plateau on the GLP-1 alone or who need additional appetite suppression in early weight loss.

The data is mostly observational. A 2022 retrospective study by Tronieri et al. in Obesity suggested adding phentermine to semaglutide could produce an additional 3% to 5% weight loss in patients who’d plateaued. The combination requires careful screening for cardiovascular contraindications and monitoring of heart rate and blood pressure.

Most patients won’t need combination therapy. For those with severe obesity who haven’t reached goals on monotherapy, it’s an option worth discussing with a prescribing clinician.

What About Cardiovascular Safety?

This is where the new data really separates the two. The SELECT trial (Lincoff et al. 2023 NEJM) tested semaglutide 2.4 mg in 17,604 adults with overweight or obesity plus established cardiovascular disease. Over 3.3 years, semaglutide reduced major adverse cardiovascular events by 20% versus placebo. That’s a striking finding for what was originally just a weight loss drug.

Phentermine doesn’t have comparable cardiovascular outcome data. Older observational studies (mainly the fen-phen era of the 1990s) raised concerns about valvular heart disease, though those signals were largely tied to fenfluramine, not phentermine itself. Modern phentermine monotherapy data is reassuring for short-term use, but no long-term randomized cardiovascular outcome trial has been done.

For patients with established cardiovascular disease, GLP-1s now have a clear cardioprotective edge. For low-cardiovascular-risk patients seeking short-term weight loss, phentermine remains a reasonable option.

Who’s a Good Candidate for Phentermine?

Phentermine fits patients who want a short, affordable jumpstart, have low cardiovascular risk, can tolerate stimulant-like side effects, and don’t have hypertension or other contraindications. It also fits patients with limited budget and limited access to GLP-1s, those who failed GLP-1s due to GI side effects, and those who only need to lose 10 to 30 pounds for a defined goal.

It doesn’t fit patients with uncontrolled hypertension, history of cardiovascular disease, hyperthyroidism, glaucoma, anxiety disorders that worsen on stimulants, or those who need substantial long-term weight loss.

Who’s a Good Candidate for GLP-1?

GLP-1s fit patients with substantial weight to lose (often 30+ pounds), comorbidities like type 2 diabetes, cardiovascular disease, sleep apnea, or chronic kidney disease, willingness to commit to long-term treatment, and the budget for either insurance-covered brand or compounded pricing.

They fit patients who’ve tried phentermine, lifestyle, or older medications without sufficient result, and patients who want a more sustained physiological approach rather than a stimulant-driven one. At TrimRx, the free assessment quiz screens for eligibility and connects qualified patients with compounded semaglutide or tirzepatide options.

Bottom line: Phentermine raises heart rate and blood pressure; GLP-1s tend to lower both

FAQ

Can I Switch From Phentermine to a GLP-1?

Yes, this is a common transition. There’s no required washout period for phentermine before starting a GLP-1, though most clinicians stop phentermine when starting a GLP-1 to assess the new medication’s effects cleanly. Some patients overlap briefly during the GLP-1 titration phase, especially if the GLP-1 hasn’t kicked in yet.

Is Phentermine Safer Than GLP-1s?

It depends on the patient. Phentermine has a cleaner GI profile but a worse cardiovascular profile. GLP-1s have GI side effects but show cardioprotection in the SELECT trial. For low-cardiovascular-risk patients, both have manageable safety profiles. For patients with cardiovascular disease, GLP-1s are clearly safer.

How Fast Does Phentermine Work?

Phentermine produces appetite suppression within hours of the first dose. Weight loss typically shows up within the first 2 weeks. Peak weight loss usually occurs around weeks 8 to 12, after which the body adapts and the effect can plateau.

Will I Regain Weight After Stopping Phentermine?

Most patients regain some weight after stopping phentermine, though long-term maintenance depends heavily on whether the weight loss period was used to build lasting habits. GLP-1s show consistent regain in trials when stopped. Phentermine’s short-term approval makes “stop and maintain” a built-in feature of the treatment plan.

Can Phentermine Cause Withdrawal?

Phentermine can cause mild rebound fatigue and increased appetite when stopped, especially after high-dose long-term use. True withdrawal in the addiction sense is rare. Tapering isn’t usually necessary but some clinicians step down the dose over a few weeks.

Does Insurance Cover Phentermine?

Phentermine is usually covered by insurance, often as a Tier 1 generic. Out-of-pocket costs are low even without insurance. This is one of phentermine’s biggest practical advantages over GLP-1s, which face heavy prior authorization hurdles for obesity indications.

Can I Take Phentermine with Caffeine?

Stacking phentermine with high caffeine intake amplifies the sympathomimetic load and can worsen heart rate, blood pressure, jitteriness, and insomnia. Most clinicians advise limiting caffeine to one moderate serving in the morning during phentermine therapy.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.